Search results :

Sorafenib

More information: STITCH, PubChem and possibly Wikipedia

ATC Code: L01XE05

Side effects

Options: Show MedDRA Preferred Terms

Side effect Data for drug Placebo Labels
1 2 3 4
Hypoalbuminaemia 0% - 58% 0% - 47% x x
Decreased appetite very common x
Arthralgia postmarketing, very common x x x x
Body temperature increased postmarketing, very common x x x x
Leukopenia postmarketing, very common x x x
Amylase increased postmarketing, very common x x x x
Tumour pain postmarketing, very common x x x x
Cerebral haemorrhage postmarketing, very common x x x x
Lymphopenia postmarketing — 6% - 47% 6% - 42% x x x
Diarrhoea postmarketing, 0% - 55% 0% - 25% x x x x
Fatigue postmarketing, 1% - 46% 1% - 45% x x x x
Dyspnoea 1% - 14% 1% - 12% x x
Anaemia postmarketing, common x x x x
Dysphagia postmarketing, common x x x x
Dermatitis exfoliative postmarketing, common x x x x
Dysgeusia postmarketing, common x x x
Dyspepsia postmarketing, common x x x x
Flushing postmarketing, common x x x x
Folliculitis postmarketing, common x x x x
Glossodynia postmarketing, common x x x x
Hyponatraemia postmarketing, common x x x x
Hypothyroidism postmarketing, common x x x x
Infarction postmarketing, common x x x x
Proteinuria postmarketing, common x x x x
Renal failure postmarketing, common x x x x
Muscle spasms postmarketing, common x x x
Thrombocytopenia postmarketing, common x x x x
Dry mouth postmarketing, common x x x x
Myocardial ischaemia postmarketing, common x x x x
Myalgia postmarketing, common x x x x
Erectile dysfunction postmarketing, common x x x x
Influenza like illness postmarketing, common x x x x
Hyperkeratosis postmarketing, common x x x
Rhinorrhoea postmarketing, common x x x x
Haemorrhage postmarketing — 0% - 15% 1% - 8% x x x x
Pain postmarketing — 0% - 31% 0% - 26% x x x x
Hepatic function abnormal 1% - 11% 1% - 8% x x
Anorexia postmarketing, 0% - 29% 0% - 18% x x x x
Abdominal pain 0% - 7% 1% - 3% x x x
Neutropenia postmarketing — 1% - 11% 1% - 14% x x x
Asthenia postmarketing — 0% - 6% 1% - 2% x x x x
Vomiting postmarketing, 0% - 16% 0% - 12% x x x x
Skin exfoliation postmarketing, 0% - 40% 0% - 16% x x x x
Cholangitis postmarketing — common x x x x
Cholecystitis postmarketing — common x x x x
Erythema multiforme uncommon x x
Interstitial pneumonia uncommon x x
Blood bilirubin increased uncommon x x x
Rash postmarketing, 0% - 40% 0% - 16% x x x x
Hypertension postmarketing, 1% - 17% 0% - 2% x x x x
Nausea postmarketing, 0% - 24% 0% - 20% x x x x
Stomatitis postmarketing — 0% - 11% 0% - 5% x x x x
Weight decreased postmarketing, 0% - 30% 0% - 10% x x x x
Mucosal inflammation postmarketing — 0% - 11% 0% - 5% x x x x
Neuropathy 0% - 13% 0% - 6% x x
Anaphylactic shock postmarketing, uncommon x x x
Dehydration postmarketing, uncommon x x x x
Eczema postmarketing, uncommon x x x x
Gastritis postmarketing, uncommon x x x x
Gynaecomastia postmarketing, uncommon x x x x
Hypertensive crisis postmarketing, uncommon x x x x
Hyperthyroidism postmarketing, uncommon x x x
Jaundice postmarketing, uncommon x x x x
Pneumonia postmarketing, uncommon x x x
Tinnitus postmarketing, uncommon x x x x
Urticaria postmarketing, uncommon x x x x
Radiation pneumonitis postmarketing, uncommon x x x
Leukoencephalopathy postmarketing, uncommon x x x
Respiratory distress postmarketing, uncommon x x x
International normalised ratio abnormal postmarketing, uncommon x x x x
Headache postmarketing, 0% - 10% 0% - 6% x x x x
Pruritus postmarketing, 0% - 19% 0% - 11% x x x x
Angioedema postmarketing x x x
Mental disorder postmarketing x x x
Bone disorder postmarketing x
Breast disorder postmarketing x x x
Skin cancer postmarketing x x x
Infection postmarketing, very common x x x x
Connective tissue disorder postmarketing x x x
Endocrine disorder postmarketing x x x
Toxic epidermal necrolysis postmarketing x x x
Gastrooesophageal reflux disease postmarketing x x x
Gastrointestinal disorder postmarketing x x x x
Cardiac disorder postmarketing x x x
Cardiac failure congestive postmarketing, common x x x x
Hypersensitivity postmarketing, uncommon x x x x
Hypocalcaemia postmarketing, common x x x
Hypokalaemia postmarketing, common x x x
Immune system disorder postmarketing x x x
Keratoacanthoma postmarketing x x x
Mediastinal disorder postmarketing x x x x
Nephrotic syndrome postmarketing, rare x x x x
Nervous system disorder postmarketing x x x x
Pancreatitis postmarketing, uncommon x x x x
Rhabdomyolysis postmarketing x x x
Stevens-Johnson syndrome postmarketing x x x
Erythema postmarketing, very common x x x x
Urinary tract disorder postmarketing x x
Angiopathy postmarketing x x x x
Hepatic failure rare x
Hypophosphataemia postmarketing — 11% - 35% 3% - 11% x x x x
Peripheral sensory neuropathy postmarketing x x x
Allergic cutaneous angiitis postmarketing x
Malnutrition postmarketing x x x x
Unspecified disorder of skin and subcutaneous tissue postmarketing x x x x
Interstitial lung disease postmarketing, uncommon x x x
Fatal outcomes postmarketing x x x x
Hepatobiliary disease postmarketing x x x x
Lipase increased postmarketing, very common x x x x
Squamous cell carcinoma of skin postmarketing x x
Infestation NOS postmarketing x x x
Blood and lymphatic system disorders postmarketing x x x
Ear and labyrinth disorders postmarketing x x x
Prothrombin level abnormal postmarketing x x x
Potassium low postmarketing x
Drug-induced hepatitis postmarketing, rare x x x
Dysphonia postmarketing x x x
Radiation recall reaction (dermatologic) postmarketing x x
Hepatocellular carcinoma postmarketing x
Osteonecrosis of jaw postmarketing x
Leukocytoclastic vasculitis postmarketing x
Constipation postmarketing, 0% - 15% 0% - 11% x x x x
Alopecia postmarketing, 0% - 27% 0% - 3% x x x x
Arrhythmia x x
Ascites x
Burning mouth syndrome x
Carcinoma x
Squamous cell carcinoma x
Transient ischaemic attack x x
Cough x
Epistaxis x x
Varices oesophageal x x
Glossitis x
Cardiac failure x
Haematoma x
Hoarseness 0% - 5% 0% - 1% x x
Ischaemia x
Renal failure acute x
Myocardial infarction x
Neoplasm x
Pain in extremity x x
Pleural effusion x
Aphthous stomatitis x
Suicide x
Syncope x
Thromboembolism x x
Vascular headache x
Urogenital disorder x
Mouth ulceration x
Acute interstitial nephritis x
Gastrointestinal perforation x x
Aspartate aminotransferase increased x x
Alanine aminotransferase increased x
Dry skin postmarketing, 0% - 11% 0% - 6% x x x x
Abdominal rigidity x
Haemoglobin decreased x
Brain cancer metastatic x
Oesophageal pain x
Oral pain x
Abdominal discomfort x
Abdominal pain upper x
Abdominal pain lower x
Abdominal tenderness x
Disease progression x
Blood pressure systolic increased x
Metastatic renal cell carcinoma x
Gastrointestinal symptom NOS x x
Blood pressure increased x
Hepatic pain x
Thyrotropin high x
Drug interaction x
Erythema multiforme minor x
Oesophageal discomfort x
Oropharyngeal discomfort x
Mood alteration NOS x

Indications

Information about indications was extracted from the indications and usage sections of the labels.

sorafenib / sorafenib

Side effects:117
Source:EMA

SORAFENIB (SORAFENIB TOSYLATE) / NEXAVAR

Side effects:119
Source:Health Canada

SORAFENIB

Side effects:131
Source:FDA Structured Product Label

Color scheme:

standard – alternative

    100%
    75%
    50%
    10%
    frequent (1% to 100%)
    infrequent (0.1% to 1%)
    rare (<0.1%)
    postmarketing
    0%
    no frequency information
    not found on label